Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib added to imatinib vs continued imatinib vs switch to nilotinib in CML-CP without deep molecular response
2024-515040-23-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Asciminib + imatinib, Continued imatinib and Switch to nilotinib (3 arms). Primary endpoint: Molecular Response (MR4.5) rate at 48 weeks. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-515040-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515040-23-00.